EP2119444B1 - Agent thérapeutique pour la douleur - Google Patents

Agent thérapeutique pour la douleur Download PDF

Info

Publication number
EP2119444B1
EP2119444B1 EP08704491.3A EP08704491A EP2119444B1 EP 2119444 B1 EP2119444 B1 EP 2119444B1 EP 08704491 A EP08704491 A EP 08704491A EP 2119444 B1 EP2119444 B1 EP 2119444B1
Authority
EP
European Patent Office
Prior art keywords
pain
sialic acid
composition
inflammatory
neuropathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP08704491.3A
Other languages
German (de)
English (en)
Other versions
EP2119444A4 (fr
EP2119444A1 (fr
Inventor
Yoshitaka Nakazawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Zoki Pharmaceutical Co Ltd
Original Assignee
Nippon Zoki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co Ltd filed Critical Nippon Zoki Pharmaceutical Co Ltd
Publication of EP2119444A1 publication Critical patent/EP2119444A1/fr
Publication of EP2119444A4 publication Critical patent/EP2119444A4/fr
Application granted granted Critical
Publication of EP2119444B1 publication Critical patent/EP2119444B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C07H7/027—Keto-aldonic acids

Definitions

  • the present invention relates to a composition for treating non-inflammatory pain containing sialic acid or a pharmaceutically acceptable salt thereof as an effective ingredient.
  • Sialic acid is a general name for acyl derivatives of neuraminic acid. Although many kinds of sialic acids are present in the natural world, N-acetylneuraminic acid is most abundant among them and then the rate of N-glycolylneuraminic acid follows. Sialic acid is widely distributed in living organisms as a constituent for glycoprotein, glycolipid, glycopeptide, etc. It exits particularly on the cell membrane surfaces of animals and microbes bearing important biological functions such as participation in specific recognition mechanism of cells. Sialic acid has been regarded as important both medically and pharmaceutically as a substance participating in cancer, inflammation, immune, viral infection, cell differentiation, hormone receptor, etc. and various studies have been carried out for sialic acid and derivatives thereof.
  • sialic acid has a specific analgesic action.
  • "Pain” is broadly classified into inflammatory pain which is caused by the inflammation of tissues by damage, etc. followed by releasing the algesic substances and physiological pain (nociceptive pain) as well as neuropathic pain which is not accompanied by the inflammation as such.
  • the neuropathic pain is a general name for the pain caused by damage and dysfunction of central nerve and peripheral nerve and also for the non-inflammatory pain such as neuropathy, etc. by drug therapy or radiation therapy.
  • Neuropathic pain causes, in addition to spontaneous pain, the symptoms such as hyperalgesia where pain threshold to nociceptive pain lowers and sharp pain (allodynia) induced by tactile stimulation which usually does not induce the pain. Once the morbid state is completed, it turns chronically whereby the outcome is very intractable unlike the inflammatory pain.
  • Examples of the neuropathic pain disease include trigeminal neuralgia, postherpetic neuralgia, strangulated neuropathy (thoracic outlet syndrome, carpal tunnel syndrome, spinal canal stenosis, etc.), complex regional pain syndrome (CRPS), diabetic neuropathy, neuropathy caused by trauma, phantom limb pain and central pain after spinal damage or cerebral apoplexy.
  • nonsteroidal analgesics such as neuropathic pain
  • nonopioid analgesics such as narcotic analgesics
  • narcotic analgesics etc.
  • sialic acid shows an analgesic action to model animals in morbid state of non-inflammatory pain and achieved the present invention.
  • sialic acid exhibits an anti-inflammatory action (refer to Patent Documents 1 and 2), there has been neither disclosure nor suggestion at all for its analgesic action to non-inflammatory pain.
  • An object of the present invention is to provide a composition for heating non-inflammatory pain.
  • sialic acid shows an analgesic action to model animals in morbid state of non-inflammatory pain
  • it is useful as an analgesic agent for non-inflammatory diseases such as neuropathic pain whereby the present invention has been achieved.
  • Sialic acid which is an effective ingredient of the drug of the present invention showed an analgesic action to model animals in morbid state of neuropathic pain which is a non-inflammatory pain. Accordingly, the analgesic agent of the present invention is useful as a drug for the treatment of non-inflammatory pain diseases such as neuropathic pain.
  • the present invention relates to a composition for use in the treatment of non-inflammatory pain containing sialic acid or a pharmaceutically acceptable salt thereof as an effective ingredient.
  • Sialic acid which is an effective ingredient of the analgesic agent of the present invention include the pharmaceutically acceptable salts of thereof with alkali metal such as sodium or potassium, with alkaline-earth metal such as calcium, magnesium or barium, with other metal such as aluminium or zinc, with organic amine or with ammonium.
  • alkali metal such as sodium or potassium
  • alkaline-earth metal such as calcium, magnesium or barium
  • other metal such as aluminium or zinc
  • organic amine or with ammonium can be produced from sialic acid in a free form, or converted reversibly, in accordance with a known method.
  • Existence of not less than 15 kinds of sialic acid has been known and many of them are N-acetyl or N-glycolyl substances and have N-acyl or O-acyl group. Any of them is able to be used in the present invention.
  • N-acetylneuraminic acid which exists most abundantly in the natural world and is a representative sialic acid and a pharmaceutically acceptable salt thereof.
  • Acute toxicity of N-acetylneuraminic acid is disclosed in Patent Document 1 and the toxicity is shown to be very low and safe.
  • sodium N-acetylneuraminate it is also shown to be very lowly toxic as a result of acute toxicity tests (refer to Example 8 of the Japanese Examined Patent Publication No. 63/028,411 ).
  • the present invention includes any and all of them.
  • the sialic acid in the present invention can be made into pharmaceutical preparations by a combination with a suitable pharmaceutical carriers or diluents according to any conventional methods, for example, preparations for oral administrations (e.g. tablets, capsules, powders, liquids, etc.) and for parenteral administrations (e.g. for subcutaneous, intravenous, intramuscular, intrarectal and intranasal administrations).
  • oral administrations e.g. tablets, capsules, powders, liquids, etc.
  • parenteral administrations e.g. for subcutaneous, intravenous, intramuscular, intrarectal and intranasal administrations.
  • the sialic acid in the present invention may also be used in the form of the pharmaceutically acceptable salt, and can be used either solely or jointly together with other pharmaceutically effective ingredients.
  • the sialic acid per se or together with an appropriate additive such as an excipient, a binder, a disintegrating agent, a lubricant, a bulking agent, a moisturizer, a buffer, a preservative or a flavor is able to be made into tablets, diluted powder, granules or capsules.
  • an appropriate additive such as an excipient, a binder, a disintegrating agent, a lubricant, a bulking agent, a moisturizer, a buffer, a preservative or a flavor
  • suitable preparations for the therapy such as injections, suppositories, inhalations, aerosols, syrups, collyriums or medicines for external use (e.g. ointments).
  • the preferred dose of the composition for use of the present invention may vary depending upon e.g. the object to be administered the patient, the form of the preparation, the method for the administration, or the term for the administration, and, in order to achieve a desired effect, 10-5000 mg per day, preferably 50-3000 mg per day may be usually given to common adults by oral route. In the case of a parenteral administration such as by injection, lower doses than the above given dose by oral route have an effect.
  • Test for analgesic effect was conducted using Chung model rats which are models of neuropathic pain.
  • Male rats of Wistar strain of 9 weeks age were used as experimental animals and model rats were prepared according to a method of Kim and Chung (Pain, vol. 50, pages 355 to 363, 1992 ).
  • Kim and Chung Pain, vol. 50, pages 355 to 363, 1992 .
  • rat L5 spinal nerve was exposed and the periphery side of L5 dorsal root ganglion was strongly ligated with 5-0 silk yarn under anesthetizing with pentobarbital (40 mg/kg, intraperitoneal administration) to conduct a nerve damage.
  • N-acetylneuraminic acid as a test substance was intraperitoneally administered in a single dose (120 mg/kg).
  • a 0.5% CMC-Na (w/v) solution/physiological saline was similarly administered to the nerve damage control group (control group).
  • pain tests were conducted and the calculated 50% reaction threshold values were expressed in terms of mean value ⁇ standard deviation for each group.
  • An example of the results of the above test is shown in Table 1. Test for significant difference was conducted using Dunnett's multiple comparison method for a comparison in multiple groups between the nerve damage control group and the test substance-administered group and it was judged that P ⁇ 0.05 is significantly different.
  • N-acetylneuraminic acid as a test substance was orally administered in a single dose (300 mg/kg). Injection solvent was administered to a nerve damage control group (control group) in the same manner. After 60 minutes from the administration of a test substance, pain tests were conducted and the 50% reaction threshold values were calculated. Numbers of the animals were eight for each of the nerve damage control group and the test substance-administered group. An example of the above test result is shown in Table 2.
  • the composition for use of the present invention is useful as a drug for the treatment of non-inflammatory pain such as neuropathic pain disease, for example, trigeminal neuralgia, postherpetic neuralgia, strangulated neuropathy (e.g.
  • thoracic outlet syndrome carpal tunnel syndrome or spinal canal stenosis
  • complex regional pain syndrome CRPS
  • diabetic neuropathy neuropathy caused by trauma, phantom limb pain, central pain after spinal damage or cerebral apoplexy and neuropathic pain caused by drug therapy or radiation therapy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Claims (6)

  1. Composition contenant de l'acide sialique ou un sel pharmaceutiquement acceptable de celui-ci pour une utilisation dans le traitement de la douleur non-inflammatoire.
  2. Composition pour une utilisation de la revendication 1, qui contient de l'acide sialique ou un sel pharmaceutiquement acceptable de celui-ci comme étant le seul ingrédient efficace.
  3. Composition pour une utilisation de la revendication 1 ou 2, dans laquelle la douleur non-inflammatoire est une douleur neuropathique.
  4. Composition pour une utilisation de la revendication 3, dans laquelle la douleur non-inflammatoire est une névralgie du trijumeau, une névralgie post-herpétique, une neuropathie par étranglement, un syndrome douloureux régional complexe (CRPS), une neuropathie diabétique, une neuropathie provoquée par un traumatisme, une douleur du membre fantôme, une douleur centrale ou une douleur neuropathique provoquée par une pharmacothérapie ou une radiothérapie.
  5. Composition pour une utilisation de l'une des revendications 1 à 4, dans laquelle l'acide sialique est l'acide N-acétylneuraminique.
  6. Composition pour une utilisation de l'une des revendications 1 à 5, qui est un agent oral.
EP08704491.3A 2007-02-08 2008-02-06 Agent thérapeutique pour la douleur Not-in-force EP2119444B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007028721A JP4005115B1 (ja) 2007-02-08 2007-02-08 疼痛疾患治療剤
PCT/JP2008/051920 WO2008096775A1 (fr) 2007-02-08 2008-02-06 Agent thérapeutique pour la douleur

Publications (3)

Publication Number Publication Date
EP2119444A1 EP2119444A1 (fr) 2009-11-18
EP2119444A4 EP2119444A4 (fr) 2010-06-09
EP2119444B1 true EP2119444B1 (fr) 2015-07-08

Family

ID=38769833

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08704491.3A Not-in-force EP2119444B1 (fr) 2007-02-08 2008-02-06 Agent thérapeutique pour la douleur

Country Status (9)

Country Link
US (1) US8492350B2 (fr)
EP (1) EP2119444B1 (fr)
JP (1) JP4005115B1 (fr)
KR (1) KR101472431B1 (fr)
CN (1) CN101600438B (fr)
AU (1) AU2008212250B2 (fr)
CA (1) CA2677026C (fr)
TW (1) TWI405576B (fr)
WO (1) WO2008096775A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116139A1 (fr) * 2008-05-08 2009-11-11 Nestec S.A. Acide sialique pour le support de la santé mentale des personnes âgées
US20110301103A1 (en) 2010-06-05 2011-12-08 Chugh Sumant S Methods of Treatment
US9827192B2 (en) 2012-05-14 2017-11-28 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9895383B2 (en) 2012-05-14 2018-02-20 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10034890B2 (en) 2012-05-14 2018-07-31 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10028908B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9700570B2 (en) 2014-05-27 2017-07-11 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9943531B2 (en) 2014-08-08 2018-04-17 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US10028969B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9707245B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10173986B2 (en) 2012-05-14 2019-01-08 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US10080765B2 (en) 2012-05-14 2018-09-25 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10039773B2 (en) 2012-05-14 2018-08-07 Antecip Bioventures Ii Llc Neridronic acid for treating arthritis
US9707247B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9956237B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9867839B2 (en) 2012-05-14 2018-01-16 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9211257B2 (en) 2012-05-14 2015-12-15 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9694023B2 (en) 2012-05-14 2017-07-04 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10111837B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds
US9949993B2 (en) 2012-05-14 2018-04-24 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10092581B2 (en) 2014-05-15 2018-10-09 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9795622B2 (en) 2012-05-14 2017-10-24 Antecip Bioventures Ii Llc Neridronic acid for treating pain associated with a joint
US9770457B2 (en) 2012-05-14 2017-09-26 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesion
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9901589B2 (en) 2012-05-14 2018-02-27 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9717747B2 (en) 2012-05-14 2017-08-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9827256B2 (en) 2014-05-27 2017-11-28 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating lower back pain
US9999628B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9789128B2 (en) 2012-05-14 2017-10-17 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10016446B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US9844559B2 (en) 2012-05-14 2017-12-19 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesions
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US9867840B2 (en) 2014-05-27 2018-01-16 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9861648B2 (en) 2012-05-14 2018-01-09 Antecip Boiventures Ii Llc Osteoclast inhibitors for knee conditions
US9782421B1 (en) 2012-05-14 2017-10-10 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9956234B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9820999B2 (en) 2012-05-14 2017-11-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9877977B2 (en) 2012-05-14 2018-01-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10004756B2 (en) 2014-05-15 2018-06-26 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9925203B2 (en) 2012-05-14 2018-03-27 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
CN103357006B (zh) * 2012-10-10 2014-10-15 日本脏器制药株式会社 含有提取物的制剂的检查方法
JP5275502B1 (ja) * 2012-10-10 2013-08-28 日本臓器製薬株式会社 抽出物及び製剤
JP5490939B2 (ja) * 2013-04-19 2014-05-14 日本臓器製薬株式会社 抽出物及び製剤
JP5844320B2 (ja) * 2013-08-23 2016-01-13 日本臓器製薬株式会社 抽出物及び該抽出物を含有する製剤
JP5844338B2 (ja) * 2013-11-19 2016-01-13 日本臓器製薬株式会社 抽出物及び該抽出物を含有する製剤
US20140348916A1 (en) * 2014-08-11 2014-11-27 Antecip Bioventures Ii Llc Treatment of Pain with Oral Dosage Forms Comprising Zoledronic Acid and An Enhancer
SG11201705801VA (en) * 2015-02-03 2017-08-30 Atsuko Morita Ingredient made from swiftlet nest as raw material, composition, and method for producing ingredient
JP6043922B2 (ja) * 2015-11-20 2016-12-14 日本臓器製薬株式会社 抽出物及び該抽出物を含有する製剤
KR101873527B1 (ko) 2016-09-02 2018-07-02 부산대학교 산학협력단 시알산 유도체를 포함하는 자궁내막증 예방 또는 치료용 조성물
JP2016216518A (ja) * 2016-09-28 2016-12-22 日本臓器製薬株式会社 抽出物及び該抽出物を含有する製剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1046051B (it) * 1975-08-13 1980-06-30 Fidia Spa Nuova applicazione terapeutica dei gangliosidi e procedimento per la loro estrazione
US4476119A (en) * 1981-08-04 1984-10-09 Fidia S.P.A. Method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions
JPS6168418A (ja) 1984-09-11 1986-04-08 Kanto Ishi Pharma Co Ltd 去痰薬
JPS62145015A (ja) 1985-12-19 1987-06-29 Kotobuki Chem:Kk 抗炎症剤
IT1212041B (it) * 1987-11-02 1989-11-08 Fidia Farmaceutici Gangliosidi esteri interni come agenti terapeutici capaci di eliminare il dolore nelle neuropatie periferiche
JP2684179B2 (ja) 1987-12-21 1997-12-03 雪印乳業株式会社 抗炎症剤
JP3286340B2 (ja) * 1991-03-06 2002-05-27 日本臓器製薬株式会社 シアル酸誘導体
US5438125A (en) 1991-03-06 1995-08-01 Nippon Zoki Pharmaceutical Co., Ltd. Sialic acid derivatives
IT1260156B (it) * 1992-08-03 1996-03-28 Fidia Spa Derivati dell'acido neuraminico
CN1160078C (zh) * 1995-05-25 2004-08-04 日本碍子株式会社 唾液酸，其盐，其聚合体或聚合体的盐的制药应用
JP4044630B2 (ja) 1996-05-16 2008-02-06 雪印乳業株式会社 脳機能改善剤
CN100400051C (zh) 2004-12-15 2008-07-09 阿尔贝拉医药控股(通化)有限公司 一种药物组合物、其制备方法及其用途
CN1305489C (zh) * 2005-08-10 2007-03-21 贵州老来福药业有限公司 一种治疗风寒湿痹的中药伤湿贴及其制备方法
CN1762486A (zh) 2005-10-28 2006-04-26 诺氏制药（吉林）有限公司 脑苷肌肽在制备防治周围神经疾病药物中的用途
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy

Also Published As

Publication number Publication date
US20100121040A1 (en) 2010-05-13
JP4005115B1 (ja) 2007-11-07
CA2677026C (fr) 2014-11-18
CN101600438A (zh) 2009-12-09
KR20090107500A (ko) 2009-10-13
TW200838545A (en) 2008-10-01
WO2008096775A1 (fr) 2008-08-14
CA2677026A1 (fr) 2008-08-14
EP2119444A4 (fr) 2010-06-09
EP2119444A1 (fr) 2009-11-18
TWI405576B (zh) 2013-08-21
AU2008212250A1 (en) 2008-08-14
JP2008189635A (ja) 2008-08-21
US8492350B2 (en) 2013-07-23
CN101600438B (zh) 2012-06-27
KR101472431B1 (ko) 2014-12-12
AU2008212250B2 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
EP2119444B1 (fr) Agent thérapeutique pour la douleur
KR102539060B1 (ko) 만누론 이산의 조성물
CN106344595B (zh) 褐藻胶寡糖及其衍生物在制备治疗疼痛药物中的应用
IL171956A (en) Use of glatiramer acetate and mitoxantrone in the manufacture of medicaments for the treatment of multiple sclerosis
EP2589382A1 (fr) Composition pharmaceutique contenant de la lévocarnitine et du dobésilate
WO2024022468A1 (fr) Utilisation de rhamnose dans la préparation d'un médicament pour le traitement ou la prévention de maladies neurodégénératives, composition pharmaceutique et son utilisation
CN109096190B (zh) 一种青藤碱衍生物及其制备方法、用途和药物组合物
CN113521072A (zh) 奈非那韦在制备防治非酒精性脂肪性肝炎和/或抗肝纤维化药物中的应用
JP2529605B2 (ja) 免疫賦活剤
JPH08512311A (ja) 慢性疲労症候群治療用ヒ素医薬
WO2022114459A1 (fr) Composition pharmaceutique destinée à prévenir ou à traiter une fibrose d'organe, comprenant du fumarate de monométhyle en tant que principe actif
DE4127469A1 (de) Arzneimittel und ihre verwendung
WO2002094019A9 (fr) Compose d'anti-endotoxine hautement purifie
EP2580227B1 (fr) Nouveaux complexes de faible poids moléculaire entre le fer et l'acide maltobionique, utilisation desdits complexes pour administration intramusculaire ou sous-cutanée dans le traitement d'états anémiques, et nouvelles compositions pharmaceutiques adaptées à ces utilisations
EP3815690A1 (fr) Application d'une composition de diacide mannuronique dans le traitement du diabète
EP1708692B1 (fr) Dichloroacetate en combinaison avec un agent inotrope pour la protection cardiaque
CN113398114B (zh) 3,7,8,4′-四羟基黄酮在制备抗心血管疾病药物中的应用
CN108938653B (zh) 氧化型1,4-β-D-葡萄糖醛酸寡糖在制备治疗阿尔茨海默病的药物中的应用
CN108245499B (zh) 大麻二酚与双链脂肪酸类抗癫痫药物的组合物及其用途
HUT73812A (en) Use of lignan derivatives for the preparation of pharmaceutical compositions for the treatment of states of amyloidosis
CN108245510B (zh) 大麻二酚与乙丙酰脲类抗癫痫药物的组合物及其用途
CN114984004A (zh) 硫酸舒欣啶在制备抗脓毒症药物中的应用
EP3127539A1 (fr) Utilisation de 2- (5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl) -acétamide dans le traitement de crises d'épilepsie
EP4279073A1 (fr) Application d'une composition contenant du cilostazol dans la préparation d'un médicament pour le traitement d'une maladie neurovasculaire
EP0516132A1 (fr) Activité antineuronotoxique et application thérapeutique du méthyl ester du ganglioside GM1

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090819

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20100510

17Q First examination report despatched

Effective date: 20111122

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150219

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 734842

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150715

Ref country code: CH

Ref legal event code: NV

Representative=s name: NOVAGRAAF INTERNATIONAL SA, CH

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008038891

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 734842

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150708

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20150708

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151009

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151008

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151109

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151108

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008038891

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160229

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

26N No opposition filed

Effective date: 20160411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160206

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160206

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20080206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150708

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20200219

Year of fee payment: 13

Ref country code: GB

Payment date: 20200219

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20200219

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20200219

Year of fee payment: 13

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602008038891

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20210206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210228

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210901

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210228

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210206